90 research outputs found
S100B Profiles and Cognitive Function at High Altitude
No full textBjursten, Henrik, Per Ederoth, Engilbert Sigurdsson, Magnus Gottfredsson, Ingvar Syk, Orri Einarsson, and Tomas Gudbjartsson. S100B profiles and cognitive function at high altitude. High Alt. Med. Biol. 11:31-38, 2010.-Exposure to high altitude can lead to acute mountain sickness (AMS) and high altitude cerebral edema (HACE). In this study we investigated the effect of high altitude on neurocognitive function and S100B release. Increased S100B release has been hypothesized to signify a loss of integrity in the blood-brain barrier (BBB). Seven healthy volunteers trekked to Capanna Regina Margherita (4554 m above sea level) in the Monte Rosa massif. During ascent and descent, five test events were undertaken; participants underwent neurocognitive testing, Lake Louise scoring (LLS), and blood sampling to measure levels of S100B. The blood tests revealed that S100B levels increased 42% to 122% from baseline, and mean LLS increased from 0.57 to 2.57. A significant correlation was observed between both S100B levelsand LLS and S100B and some neurocognitive scores. The study indicates that S100B can be released by a mild hypoxia during AMS. Moreover, an observed correlation between S100B and a lower score on neurocognitive tests suggests that the pathogenetic mechanisms may be linked. The study indicates that a decline in cognitive function is associated with symptoms of AMS
S100B Profiles and Cognitive Function at High Altitude
No full textBjursten, Henrik, Per Ederoth, Engilbert Sigurdsson, Magnus Gottfredsson, Ingvar Syk, Orri Einarsson, and Tomas Gudbjartsson. S100B profiles and cognitive function at high altitude. High Alt. Med. Biol. 11:31-38, 2010.-Exposure to high altitude can lead to acute mountain sickness (AMS) and high altitude cerebral edema (HACE). In this study we investigated the effect of high altitude on neurocognitive function and S100B release. Increased S100B release has been hypothesized to signify a loss of integrity in the blood-brain barrier (BBB). Seven healthy volunteers trekked to Capanna Regina Margherita (4554 m above sea level) in the Monte Rosa massif. During ascent and descent, five test events were undertaken; participants underwent neurocognitive testing, Lake Louise scoring (LLS), and blood sampling to measure levels of S100B. The blood tests revealed that S100B levels increased 42% to 122% from baseline, and mean LLS increased from 0.57 to 2.57. A significant correlation was observed between both S100B levels and LLS and S100B and some neurocognitive scores. The study indicates that S100B can be released by a mild hypoxia during AMS. Moreover, an observed correlation between S100B and a lower score on neurocognitive tests suggests that the pathogenetic mechanisms may be linked. The study indicates that a decline in cognitive function is associated with symptoms of AMS
Unveiling New Aspects of Meningococcal Carriage and Disease Prevention.
No full textTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files.
This article is open access.Recently, two protein-based vaccines have been approved for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB). It is therefore important to study carefully if and how these pathogens respond to widespread vaccination. Traditionally, meningococci have been classified on the basis of capsular phenotypes, but variable levels of capsule expression can influence the results, mainly among MenB strains. In this issue, Jones and colleagues (J Clin Microbiol 54:25-34, 2016, http://dx.doi.org/10.1128/JCM.01447-15) compare whole-genome sequencing to traditional phenotypic methods of classifying meningococci. They demonstrate that for MenB in particular, sequencing-based methods are far superior to traditional methods, especially when it comes to characterizing carriage isolates. This has important implications for future surveillance
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents
No full textPublisher's version (útgefin grein)A nationwide programme for the treatment of all patients infected with hepatitis C virus (HCV) was launched in Iceland in January 2016. By providing universal access to direct‐acting antiviral agents to the entire patient population, the two key aims of the project were to (i) offer a cure to patients and thus reduce the long‐term sequelae of chronic hepatitis C, and (ii) to reduce domestic incidence of HCV in the population by 80% prior to the WHO goal of HCV elimination by the year 2030. An important part of the programme is that vast majority of cases will be treated within 36 months from the launch of the project, during 2016–2018. Emphasis is placed on early case finding and treatment of patients at high risk for transmitting HCV, that is people who inject drugs (PWID), as well as patients with advanced liver disease. In addition to treatment scale‐up, the project also entails intensification of harm reduction efforts, improved access to diagnostic tests, as well as educational campaigns to curtail spread, facilitate early detection and improve linkage to care. With these efforts, Iceland is anticipated to achieve the WHO hepatitis C elimination goals well before 2030. This article describes the background and organization of this project. Clinical trial number: NCT02647879.Sigurdur Olafsson: Speaker's fee from Merck. Magnus Gottfredsson: Speaker's fee from Astellas and Gilead. MH and the Burnet Institute receive investigator‐initiated research funding from Gilead Sciences, AbbVie and BMS.Peer Reviewe
Neisseria meningitidis sequence type and risk for death, Iceland
No full textInvasive meningococcal infections are hyperendemic in Iceland, a relatively isolated country in the mid-Atlantic. We performed a nationwide study on all viable meningococcal strains (N = 362) from 1977 to 2004. We analyzed the association of patient's age and sex, meningococcal serogroups, and sequence types (STs) with outcomes. Overall, 59 different STs were identified, 19 of which were unique to Iceland. The most common STs were 32 (24.6%), 11 (19.9%), and 10 (10.2%). The unique ST-3492 ranked fourth (7.7%). The most common serogroups were B (56.4%), C (39.8%), and A (2.2%). Age (p < 0.001) and infection with a unique ST (p = 0.011) were independently associated with increased death rates, whereas isolation of meningococci from cerebrospinal fluid only was associated with lower death rates (p = 0.046). This study shows evolutionary trends of meningococcal isolates in a relatively isolated community and highlights an association between unique STs and poor outcome
Disseminated invasive aspergillosis in a patient with acute leukaemia
No full textTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldA 46-year-old previously healthy woman was diagnosed with acute lymphoblastic leukaemia. The induction phase was complicated by alpha-haemolytic streptococcal bacteremia which responded to antibacterial therapy. Subsequently, the patient developed pneumonie due to Chlamydiapneumoniae which responded to macrolides. Following this infection the patient developed recurrent fever and new pulmonary infiltrates were noted. Bronchoscopy was performed and treatment was administered with liposomal amphotericin B (L-AmB, AmBisome) for two days, but was complicated by acute renal failure. Aspergillus fumigatus was cultured from bronchoalveolar lavage fluid (three samples). L-AmB was discontinued and voriconazole and caspofungin were administered. Despite aggressive antifungal therapy the patient developed progressive invasive infection, with central nervous system involvement as well as lesions appearing in the kidneys and liver. The patient died one week following the diagnosis of aspergillosis
Disseminated invasive aspergillosis in a patient with acute leukaemia
No full textTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldA 46-year-old previously healthy woman was diagnosed with acute lymphoblastic leukaemia. The induction phase was complicated by alpha-haemolytic streptococcal bacteremia which responded to antibacterial therapy. Subsequently, the patient developed pneumonie due to Chlamydiapneumoniae which responded to macrolides. Following this infection the patient developed recurrent fever and new pulmonary infiltrates were noted. Bronchoscopy was performed and treatment was administered with liposomal amphotericin B (L-AmB, AmBisome) for two days, but was complicated by acute renal failure. Aspergillus fumigatus was cultured from bronchoalveolar lavage fluid (three samples). L-AmB was discontinued and voriconazole and caspofungin were administered. Despite aggressive antifungal therapy the patient developed progressive invasive infection, with central nervous system involvement as well as lesions appearing in the kidneys and liver. The patient died one week following the diagnosis of aspergillosis
Improving survival of patients with candidaemia: analysis of prognostic factors from a long-term, nationwide study in Iceland
No full textTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldA population-based epidemiological and clinical study of candidaemia in Iceland was conducted during a 20-y period, 1980-1999. As previously reported, the incidence of candidaemia increased 3.5-fold during the study period, without major changes in species distribution or antifungal resistance (Asmundsdottir et al., J Clin Microbiol 2002;40:3489-92). In this study detailed clinical information was collected and registered on all candidaemic patients (n=165, episodes n=172) in Iceland during 1980-1999. Clinical characteristics were compared between adults and children. Univariate and multivariate analyses were used to determine predictors of 30-d mortality. In comparison with adults, young children with candidaemia more often presented with respiratory distress, without fever p<0.001. Adult patients were more likely to have underlying malignancies (p=0.009) and to have undergone surgical operations (p=0.002). During the study a steady decrease in 30-d case fatality ratio was noted, from 58.8% in 1980-1984, to 26.7% in 1995-1999 (p=0.02). At the same time a more aggressive approach to candidaemia management was documented. In multivariate analysis, prompt removal of central venous catheters (odds ratio for death, 0.22, p=0.004), and septic shock (odds ratio for death, 8.01, p=0.001) were the strongest independent predictors of outcome. Our results underline the strong association between prompt removal of vascular catheters and favourable outcome, suggesting that mortality may be reduced by more aggressive management
Public views on antidepressant treatment: lessons from a national survey
No full textTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldIn Iceland, antidepressant sales figures rose from 8 Defined Daily Doses (DDD) per 1000 subjects in 1975 to 95 DDD/1000 in 2005. The aim of the study was to examine the views of adult Icelanders on antidepressant treatment and to identify the factors most influential in shaping their views, using cross-sectional national survey of views on antidepressant treatment in a randomly drawn sample of 2000 Icelanders aged 18-80 years old. Nine in 10 responders believed that regular exercise is an efficacious treatment for depression (92.6%) but supportive interviews came second (82.3%). Seven out of 10 believed that antidepressants are efficacious and the same proportion was willing to use antidepressants as a treatment for depression. The strongest predictor of this inclination was previous use of antidepressants (odds ratio, OR=6.9, 95% CI 3.4-13.8), followed by knowing someone well who had been treated with antidepressants (OR=2.3, 95% CI 1.6 to 3.3). Eight out of every 100 responders were taking antidepressants and further 8.3% had previously been on antidepressants for at least 6 weeks. Among past users of antidepressants, 77% felt that the benefits of therapy had outweighed the disadvantages. More knowledge on antidepressants was associated (chi-squared test=9.96, df=2, P=0.007) with willingness to use them. The majority of adult Icelanders are willing to use antidepressants for depression. The factors influencing their views most strongly are subjects' own experience and the experience of close friends or relatives as users
Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011.
No full textTo access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.Candidemia is often a life-threatening infection, with highly variable incidence among countries. We conducted a nationwide study of candidemia in Iceland from 2000 to 2011, in order to determine recent trends in incidence rates, fungal species distribution, antifungal susceptibility patterns, and concurrent antifungal consumption. A total of 208 infection episodes in 199 patients were identified. The average incidence during the 12 years was 5.7 cases/100,000 population/year, which was significantly higher than that from 1990 to 1999 (4.3/100,000/year; P = 0.02). A significant reduction in the use of blood cultures was noted in the last 3 years of the study, coinciding with the economic crisis in the country (P 60 years, and varied by gender. Age-specific incidence among males >80 years old was 28.6/100,000/year, and it was 8.3/100,000/year for females in this age group (P = 0.028). The 30-day survival rate among adult patients remained unchanged compared to that from 1990 to 1999 (70.4% versus 69.5%, P = 0.97). Candida albicans was the predominant species (56%), followed by C. glabrata (16%) and C. tropicalis (13%). The species distribution remained stable compared to that from previous decades. Fluconazole use increased 2.4-fold from 2000 to 2011, with no increase in resistance. In summary, the incidence of candidemia in Iceland has continued to increase but may have reached a steady state, and no increase in antifungal drug resistance has been noted. Decreased use of blood cultures toward the end of the study may have influenced detection rates.Eggert V. Briem Memorial Fund ,
Landspitali University Hospital Research Fun
- …
